Sutro Biopharma, Inc. (STRO)
NASDAQ: STRO · Real-Time Price · USD
34.87
+1.28 (3.81%)
At close: Apr 28, 2026, 4:00 PM EDT
34.69
-0.18 (-0.52%)
After-hours: Apr 28, 2026, 4:10 PM EDT
Sutro Biopharma Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Sutro Biopharma stock have an average target of 28, with a low estimate of 8.00 and a high estimate of 55. The average target predicts a decrease of -19.70% from the current stock price of 34.87.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Sutro Biopharma stock from 9 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 0 | 0 | 0 | 2 | 2 |
| Buy | 1 | 1 | 2 | 2 | 3 | 4 |
| Hold | 5 | 6 | 5 | 5 | 2 | 2 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 8 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citizens | Citizens | Buy Maintains $35 → $41 | Buy | Maintains | $35 → $41 | +17.58% | Apr 23, 2026 |
| Citizens | Citizens | Buy Maintains $23 → $35 | Buy | Maintains | $23 → $35 | +0.37% | Apr 17, 2026 |
| Deutsche Bank | Deutsche Bank | Strong Buy Maintains $51 → $55 | Strong Buy | Maintains | $51 → $55 | +57.73% | Mar 25, 2026 |
| Wells Fargo | Wells Fargo | Hold → Buy Upgrades $8 → $27 | Hold → Buy | Upgrades | $8 → $27 | -22.57% | Mar 24, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold → Strong Buy Upgrades $10 → $28 | Hold → Strong Buy | Upgrades | $10 → $28 | -19.70% | Mar 24, 2026 |
Financial Forecast
Revenue This Year
35.08M
from 102.48M
Decreased by -65.77%
Revenue Next Year
32.27M
from 35.08M
Decreased by -8.00%
EPS This Year
-8.57
from -22.49
EPS Next Year
-8.96
from -8.57
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 63.0M | 72.5M | ||||||
| Avg | 35.1M | 32.3M | ||||||
| Low | 9.8M | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -38.5% | 106.5% | ||||||
| Avg | -65.8% | -8.0% | ||||||
| Low | -90.4% | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -1.10 | -4.79 | ||||||
| Avg | -8.57 | -8.96 | ||||||
| Low | -11.97 | -13.66 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.